Moreover, the 36-month beta value for SANA is 1.64. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SANA is 123.02M and currently, short sellers hold a 21.72% of that float. On May 09, 2024, SANA’s average trading volume was 2.10M shares.
SANA) stock’s latest price update
Sana Biotechnology Inc (NASDAQ: SANA)’s stock price has gone decline by -5.48 in comparison to its previous close of 10.04, however, the company has experienced a -1.45% decrease in its stock price over the last five trading days. Zacks Investment Research reported 2024-05-03 that Notable companies to have witnessed solid earnings acceleration as of now are Sana Biotechnology (SANA), LifeMD (LFMD), Evolus (EOLS) and Expro Group Holdings (XPRO).
SANA’s Market Performance
Sana Biotechnology Inc (SANA) has experienced a -1.45% fall in stock performance for the past week, with a 1.61% rise in the past month, and a 55.57% rise in the past quarter. The volatility ratio for the week is 5.74%, and the volatility levels for the past 30 days are at 6.30% for SANA. The simple moving average for the past 20 days is 6.83% for SANA’s stock, with a 60.16% simple moving average for the past 200 days.
Analysts’ Opinion of SANA
Many brokerage firms have already submitted their reports for SANA stocks, with H.C. Wainwright repeating the rating for SANA by listing it as a “Buy.” The predicted price for SANA in the upcoming period, according to H.C. Wainwright is $12 based on the research report published on January 16, 2024 of the current year 2024.
JMP Securities, on the other hand, stated in their research note that they expect to see SANA reach a price target of $9. The rating they have provided for SANA stocks is “Mkt Outperform” according to the report published on September 25th, 2023.
Citigroup gave a rating of “Buy” to SANA, setting the target price at $8 in the report published on September 05th of the previous year.
SANA Trading at 2.79% from the 50-Day Moving Average
After a stumble in the market that brought SANA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.92% of loss for the given period.
Volatility was left at 6.30%, however, over the last 30 days, the volatility rate increased by 5.74%, as shares surge +5.44% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.53% lower at present.
During the last 5 trading sessions, SANA fell by -1.45%, which changed the moving average for the period of 200-days by +58.70% in comparison to the 20-day moving average, which settled at $8.91. In addition, Sana Biotechnology Inc saw 132.60% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SANA starting from Yang Patrick Y, who sale 25,000 shares at the price of $9.45 back on Mar 08 ’24. After this action, Yang Patrick Y now owns 149,250 shares of Sana Biotechnology Inc, valued at $236,300 using the latest closing price.
NELSEN ROBERT, the Director of Sana Biotechnology Inc, purchase 1,818,181 shares at $5.50 during a trade that took place back on Feb 08 ’24, which means that NELSEN ROBERT is holding 12,446,022 shares at $9,999,996 based on the most recent closing price.
Stock Fundamentals for SANA
The total capital return value is set at -0.56. Equity return is now at value -72.00, with -40.81 for asset returns.
Based on Sana Biotechnology Inc (SANA), the company’s capital structure generated 0.27 points at debt to capital in total, while cash flow to debt ratio is standing at -2.44. The debt to equity ratio resting at 0.36. The interest coverage ratio of the stock is 144.84.
Currently, EBITDA for the company is -294.94 million with net debt to EBITDA at 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.31.
Conclusion
To wrap up, the performance of Sana Biotechnology Inc (SANA) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
